Autonomix Medical, Inc. announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse split will take effect at 12:01 am (Eastern Time) on June 24, 2026. Trading on The Nasdaq Capital Market will commence on a post-split basis the same day under the existing ticker symbol "AMIX" but with a new CUSIP number 05330T304.

As a result of the reverse stock split, every 21 shares of the Company's common stock issued and outstanding prior to the opening of trading on June 24, 2026 will be consolidated into one issued and outstanding share. The nominal par value per share of $0.001 remains unchanged. No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment in lieu of that share.

Share Structure Impact

The reverse split significantly reduces the number of shares outstanding. The total authorized shares of common stock remain unchanged at 500 million shares. Additionally, the number of shares reserved for issuance under the Company's equity compensation plan will be reduced proportionately.

Autonomix is a medical device company focused on advancing technologies to revolutionize the diagnosis and treatment of diseases involving the nervous system. The Company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals. The technology is currently investigational and has not yet been cleared for marketing in the United States.

Autonomix Medical, Inc. today announced the release of its latest CEO Corner segment, highlighting the growing scientific and clinical recognition of its nerve-sensing and transvascular denervation platform technology. The company has secured 13 abstract acceptances since last fall, including nine podium presentations and four poster presentations at leading global medical conferences. This peer-reviewed recognition validates the novelty and potential impact of its technology platform for treating complex conditions like pancreatic cancer pain.

President and Chief Executive Officer Brad Hauser outlined the company's progress in the segment, emphasizing the significance of the acceptances at forums such as the Transcatheter Cardiovascular Therapeutics (TCT), Cardiovascular Research Technologies (CRT), Society of Interventional Radiology (SIR), and the American Society of Clinical Oncology Annual Meeting (ASCO). Autonomix received a top Cardiovascular Innovation Award at CRT, further distinguishing its platform technology.

Clinical and Strategic Milestones

The company's real-time nerve sensing and targeted therapy approach is designed to transform treatment paradigms. The recent accolades are expected to support physician adoption, future clinical trials, strategic partnerships, and reimbursement discussions. Autonomix is currently preparing for a planned U.S. clinical study to further evaluate its technology.

Platform Technology Overview

Autonomix's first-in-class platform system features a catheter-based microchip sensing array. The technology aims to detect and differentiate neural signals with greater sensitivity than currently available options. Initial development efforts focus on treating pain associated with pancreatic cancer, a condition with limited reliable solutions. The platform holds potential for broader applications across cardiology, hypertension, and chronic pain management. The technology remains investigational and has not yet been cleared for marketing in the United States.